PharmaEngine Cash Flow Conversion Efficiency

Latest as of September 2025: 0.011x

PharmaEngine cash flow conversion efficiency. Based on the latest financial reports, PharmaEngine (4162) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.01 Million ≈ $1.67 Million USD) by net assets (NT$4.79 Billion ≈ $151.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of PharmaEngine (2009–2024)

Cash flow conversion efficiency of PharmaEngine from 2009 to 2024. This chart illustrates how PharmaEngine's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 4162 live share price for real-time trading data and today's change.

PharmaEngine Cash Flow Conversion Ratio Explained

PharmaEngine cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

PharmaEngine Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PharmaEngine ranked by their cash flow conversion efficiency. Also see 4162 stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Velos Acquisition I Corp. NASDAQ:VLOS	-0.003x
P.C.B Tec TA:PCBT	0.056x
NEOBO FASTIGHETER ST:NEOBO	0.006x
INTERGRATED DIA.H DL 025 F:8I8	0.096x
Information Services Group Inc NASDAQ:III	-0.009x
COG Financial Services Ltd AU:COG	0.198x
Hyulim ROBOT Co.Ltd KQ:090710	-0.070x
Thu Dau Mot Water JSC VN:TDM	-0.009x

Annual Cash Flow Conversion Efficiency for PharmaEngine (2009–2024)

The table below shows the annual cash flow conversion efficiency of PharmaEngine from 2009 to 2024. Review PharmaEngine (4162) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.40 Billion ≈ $170.12 Million	NT$456.73 Million ≈ $14.39 Million	0.085x	+27.15%
2023-12-31	NT$3.86 Billion ≈ $121.70 Million	NT$256.97 Million ≈ $8.10 Million	0.067x	+27.51%
2022-12-31	NT$3.87 Billion ≈ $121.99 Million	NT$202.01 Million ≈ $6.36 Million	0.052x	-77.90%
2021-12-31	NT$3.94 Billion ≈ $124.09 Million	NT$929.67 Million ≈ $29.29 Million	0.236x	+1361.78%
2020-12-31	NT$4.01 Billion ≈ $126.37 Million	NT$64.77 Million ≈ $2.04 Million	0.016x	+249.80%
2019-12-31	NT$3.48 Billion ≈ $109.73 Million	NT$16.08 Million ≈ $506.55K	0.005x	-97.71%
2018-12-31	NT$3.69 Billion ≈ $116.38 Million	NT$745.23 Million ≈ $23.48 Million	0.202x	+332.53%
2017-12-31	NT$3.91 Billion ≈ $123.22 Million	NT$-339.30 Million ≈ $-10.69 Million	-0.087x	-137.86%
2016-12-31	NT$3.80 Billion ≈ $119.68 Million	NT$870.38 Million ≈ $27.42 Million	0.229x	+61.57%
2015-12-31	NT$3.16 Billion ≈ $99.53 Million	NT$447.99 Million ≈ $14.11 Million	0.142x	+216.59%
2014-12-31	NT$2.93 Billion ≈ $92.20 Million	NT$131.09 Million ≈ $4.13 Million	0.045x	+357.03%
2013-12-31	NT$2.72 Billion ≈ $85.63 Million	NT$-47.37 Million ≈ $-1.49 Million	-0.017x	-141.46%
2012-12-31	NT$1.63 Billion ≈ $51.45 Million	NT$68.64 Million ≈ $2.16 Million	0.042x	-90.56%
2011-12-31	NT$618.48 Million ≈ $19.49 Million	NT$275.49 Million ≈ $8.68 Million	0.445x	+163.34%
2010-12-31	NT$81.42 Million ≈ $2.57 Million	NT$-57.26 Million ≈ $-1.80 Million	-0.703x	+91.23%
2009-12-31	NT$11.29 Million ≈ $355.76K	NT$-90.54 Million ≈ $-2.85 Million	-8.018x	--

About PharmaEngine

TWO:4162 Taiwan Biotechnology

Market Cap

$251.30 Million

NT$7.98 Billion TWD

Market Cap Rank

#15383 Global

#680 in Taiwan

Share Price

NT$56.30

Change (1 day)

-1.75%

52-Week Range

NT$53.00 - NT$73.80

All Time High

NT$178.54